Menu
  • Join
  • Login
  • Contact
 

Search abstracts


EFFICACY AND SAFETY ASESSMENT OF GENERIC AND BRAND-NAME DRUG ROSUVASTATIN IN DYSLIPIDEMIA MANAGEMENT

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: CHUNG, Ming-Chieh (Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Department of Pharmacy, China Taiwan)
  • Co-author(s): Ming-Chieh Chung: Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, China Taiwan
    Hui-Qi Liu: Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, China Taiwan
  • Abstract:

    Background

    Generic drugs are therapeutic equivalent to their brand-name drugs. However, some may concern generic drugs do not work as well as brand-name drugs. Many reports indicated genetic rosuvastatin may not be equivalent to brand-name drugs (CRESTOR®) in treating hyperlipidemia.

    Methods

    We did a retrospective study from Jan. 2015 to Dec. 2017. In

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 21 September 2019

FIP Congresses